Recent Posts
- Elutia Announces $13.26 Million Registered Direct Offering
- Elutia Announces FDA Clearance of EluPro™: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators
- Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance
- Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
- Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1